|
USA-OH-CINNATI Azienda Directories
|
Azienda News:
- 2025 Alzheimer’s Drug Pipeline Shows Growth and Diversity
Led by Professor Jeffrey Cummings and colleagues, the annual review tracks global clinical trials registered on ClinicalTrials gov, offering a comprehensive snapshot of current drug development efforts in AD Key Findings from the 2025 Pipeline: 138 drugs are being tested across 182 clinical trials, with increases in all phases compared to 2024
- Alzheimer’s Clinical Trials News Roundup: Q4 | Being Patient
After months of delays, Alzheon gears up to present data from their pivotal Phase 3 drug trial, while Athira Pharma pays out a settlement to federal agencies related to their failed drug — and other Q4 updates from the world of Alzheimer’s research and trials
- Alzheimer’s Disease: Some trials to watch over the next year
Earlier this year, Eli Lilly announced it had met the primary endpoint in a Phase III study of donanemab, having slowed clinical decline in patients with mild to moderate Alzheimer’s disease by 35% compared to placebo
- Updates in Therapeutic Development: Clinical Trial Readouts to Watch in . . .
This international, multicenter, double-blind trial will measure the annualized percent brain volume change as the primary endpoint, with secondary endpoints including whole brain atrophy rate and time to 24-week confirmed disability progression on the EDSS
- Current therapeutics for Alzheimer’s disease and clinical trials
Clinical trials for Alzheimer’s disease As of May 2024, there are a total of 3,388 Alzheimer’s disease clinical trials including all studies (clinicaltrials gov) We chose to focus on the trials starting from 01 01 2015 and encompassing the past 10 years, including 2,030 studies
- Endpoints in Alzheimer’s disease clinical trials
An educational overview of clinical trial endpoints currently used in Alzheimer’s disease This interactive brochure helps better understand what the different clinical endpoints in Alzheimer’s disease are and the relevance of common Alzheimer’s disease endpoints from the perspective of clinical teams
- Alzheimer’s disease: Rise in new drugs being trialled . . . - The BMJ
The 2025 pipeline review found that there were 182 clinical trials assessing 138 drugs as at 1 January This was up from 164 trials assessing 127 drugs in 2024 An additional 56 trials have been added to the pipeline in the past year, while 25 trials were completed, eight were terminated, and eight became of “unknown status”—meaning no
- Clinical Meaningfulness in Alzheimer’s Disease Clinical Trials. A . . .
Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer’s disease, following several decades of failures Indeed, all three trials have met their primary endpoints
- Trends in Alzheimer’s Disease clinical outcome assessments in phase 2 . . .
Phase 2 and 3 Interventional AD trials were further analyzed for inclusion of 6000+ COAs in the primary or secondary outcome measures field Result: 997 studies were identified with start dates from 1993-2025
|
|